Waltham, MA – According to filings with the U.S. Securities and Exchange Commission, Regenacy Pharmaceuticals is raising $40,707,421.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Simon Jones played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Regenacy Pharmaceuticals

Regenacy Pharmaceuticals is developing a novel, disease-modifying approach to treating peripheral neuropathies that goes beyond pain and symptom management to restore peripheral nerve function. Our lead compound ricolinostat (ACY-1215) is an oral, selective inhibitor of the microtubule modifying enzyme HDAC6 with first-in-class potential, that will be entering a proof-of-concept (PoC) Phase 2 clinical trial in diabetic peripheral neuropathy. Our investigation of ricolinostat for diabetic, chemotherapy-induced, and inherited peripheral neuropathies is based on compelling PoC preclinical studies demonstrating restoration of normal nerve function.

To learn more about Regenacy Pharmaceuticals, visit http://regenacy.com/

Contact:
Simon Jones, President and Chief Executive Officer
617-415-5030
sjones@regenacy.com
https://www.linkedin.com/in/simon-jones-ph-d-09ab12b/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved